The Accelerating Medicines Partnership (AMP) in Common Metabolic Diseases (CMD) Knowledge Portal: Roadmap for Future Development (Cooperative Agreement, Clinical Trial Optional)

The Accelerating Medicines Partnership (AMP) is a public-private collaboration managed by the National Institutes of Health (NIH), aimed at fostering progress in the development of new therapeutic approaches for complex and multifaceted diseases. A central goal of AMP is to use genetic data from human populations to uncover disease mechanisms and identify potential therapeutic and biomarker opportunities. The AMP initiative brings together federal agencies, academic institutions, and the private sector in a pre-competitive space to share data and accelerate biomedical discoveries. Within this broader initiative, the AMP in Common Metabolic Diseases (AMP CMD) focuses specifically on common metabolic conditions, including Type 2 Diabetes (T2D), and aims to expand understanding of these conditions by leveraging human-derived genetic and phenotypic data. The specific opportunity described under announcement number NOT-DK-26-313 represents a forecasted cooperative agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a branch of NIH. The grant supports the continued development and improvement of the AMP CMD Knowledge Portal. This portal serves as a data integration and dissemination tool designed to collate, curate, and provide access to large-scale genotype and phenotype datasets relevant to T2D and associated conditions. The objective of this initiative is to facilitate open access to integrated human omics data and analytical tools, enabling the scientific community to explore the biological pathways underlying T2D and related metabolic disorders. The funding opportunity aims to support one grantee under a cooperative agreement mechanism. The anticipated total funding available for this effort is $3,000,000. The project period is expected to begin on December 1, 2026, and continue for five years. Award amounts, floor, and ceiling are not explicitly stated in the announcement and require verification upon final release. The anticipated posting date of the full funding announcement is October 1, 2025, with the estimated application due date set for March 1, 2026. The proposed funding falls under the Assistance Listing number 93.847, designated for Diabetes, Digestive, and Kidney Diseases Extramural Research. The AMP CMD Knowledge Portal is envisioned as a dynamic platform that will aggregate genetic association data, functional annotation of genetic variants, and integrative omics data relevant to metabolic diseases. The renewal and expansion of this portal aim to ensure its ongoing utility to the biomedical research community. It is expected that the recipient will manage data quality, provide user support, and collaborate with NIH staff to enhance the utility of the portal. Although clinical trials are optional, the project primarily emphasizes data aggregation, integration, and usability improvements. Eligibility for this opportunity is broad and includes nonprofit organizations (excluding institutions of higher education), state and local governments, tribal governments (both federally recognized and other tribal organizations), public and private institutions of higher education, small and other for-profit organizations, public housing authorities, independent school districts, and special district governments. Additionally, regional organizations, U.S. territories, and certain faith-based and community-based organizations are also eligible. The opportunity is available to all U.S. states and is nationwide in scope. The primary contact for this forecasted opportunity is Dr. Norann Zaghloul at the National Institute of Diabetes and Digestive and Kidney Diseases. She can be reached at 301-435-6677 or via email at norann.zaghloul@nih.gov. Because this is a forecasted notice, applicants should closely monitor the Grants.gov listing for updates and publication of the final notice. Applicants are encouraged to prepare early and engage with NIH representatives as permitted during the pre-application period.